We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-13.06%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$146M
AUM Growth
-$56.5M
(-28%)
Cap. Flow
+$52.6M
Cap. Flow
% of AUM
36.07%
Top 10 Holdings %
Top 10 Hldgs %
57.31%
Holding
49
New
10
Increased
16
Reduced
6
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NEOS
Neos Therapeutics, Inc
NEOS
|
+$14.7M |
| 2 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$7.61M |
| 3 |
UnitedHealth
UNH
|
+$6.7M |
| 4 |
Sanofi
SNY
|
+$6.68M |
| 5 |
United Therapeutics
UTHR
|
+$6.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$10.6M |
| 2 |
Addus HomeCare
ADUS
|
+$5.18M |
| 3 |
AET
Aetna Inc
AET
|
+$5.1M |
| 4 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$4.48M |
| 5 |
Stryker
SYK
|
+$3.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.31% |
| 2 | Miscellaneous | 1.69% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QTNT
1
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $16.7M | 11.43% |
39,511
+12,186
| +45% | +$7.61M |
|
|
NEOS
2
DELISTED
Neos Therapeutics, Inc
NEOS
| $14M | 9.6% |
+666,729
| New | +$14.7M |
|
3
Johnson & Johnson
JNJ
$646B
| $7.98M | 5.47% |
85,438
+21,261
| +33% | +$2.06M |
|
4
Medtronic
MDT
$117B
| $7.58M | 5.2% |
113,289
+57,889
| +104% | +$4.26M |
|
5
Cardinal Health
CAH
$54.6B
| $7.29M | 5% |
94,868
+31,590
| +50% | +$2.64M |
|
|
6
UnitedHealth
UNH
$353B
| $6.5M | 4.45% |
+55,984
| New | +$6.7M |
|
|
7
Sanofi
SNY
$107B
| $6.23M | 4.27% |
+131,271
| New | +$6.68M |
|
8
Cigna
CI
$73.7B
| $6.14M | 4.21% |
45,493
+27,853
| +158% | +$4.04M |
|
|
RXDX
9
DELISTED
Ignyta, Inc.
RXDX
| $5.99M | 4.11% |
682,306
+159,550
| +31% | +$2.29M |
|
10
Amgen
AMGN
$234B
| $5.23M | 3.59% |
37,832
+9,483
| +33% | +$1.49M |
|
11
Alnylam Pharmaceuticals
ALNY
$31.7B
| $5.22M | 3.58% |
64,996
+37,996
| +141% | +$4.22M |
|
|
ANTH
12
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $5.21M | 3.57% |
107,009
+77,239
| +259% | +$5.4M |
|
13
AbbVie
ABBV
$451B
| $5.13M | 3.52% |
94,316
+61,025
| +183% | +$3.97M |
|
|
DMK
14
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $5.06M | 3.47% |
18,669
+1,208
| +7% | +$336K |
|
|
15
United Therapeutics
UTHR
$22.1B
| $4.95M | 3.39% |
+37,677
| New | +$6.04M |
|
16
Bristol-Myers Squibb
BMY
$136B
| $4.9M | 3.36% |
+82,734
| New | +$5.25M |
|
17
Ascendis Pharma A/S
ASND
$16.3B
| $4.78M | 3.27% |
269,785
+67,260
| +33% | +$1.31M |
|
|
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.91M | 2.68% |
239,698
-80,302
| -25% | -$1.77M |
|
|
PFNX
19
DELISTED
Pfenex Inc.
PFNX
| $3.83M | 2.63% |
255,303
-90,825
| -26% | -$1.85M |
|
|
ACHN
20
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.52M | 1.73% |
364,368
+117,368
| +48% | +$956K |
|
|
FOMX
21
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.46M | 1.69% |
336,286
+175,000
| +109% | +$1.78M |
|
|
CYBX
22
DELISTED
CYBERONICS INC
CYBX
| $2.46M | 1.69% |
+40,478
| New | +$2.54M |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.98M | 1.36% |
57,605
+49,597
| +619% | +$1.5M |
|
|
NTUS
24
DELISTED
Natus Medical Inc
NTUS
| $1.97M | 1.35% |
+50,000
| New | +$2.12M |
|
|
ADMS
25
DELISTED
Adamas Pharmaceuticals
ADMS
| $1.7M | 1.17% |
+101,766
| New | +$2.32M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Sio Capital Management held 49 positions worth $146M, down 28% from $202M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sio Capital Management deployed $52.6M of net new capital in Q3 2015, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Neos Therapeutics, Inc: 666,729 shares worth $14M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Aratana Therapeutics, Inc., an estimated $4.48M trimmed.
- Sio Capital Management's largest Q3 2015 buy was Neos Therapeutics, Inc: 666,729 shares worth $14M.
- Sio Capital Management added most to Quotient Limited Ordinary Shares in Q3 2015, an estimated $7.61M increase.
- Sio Capital Management's biggest Q3 2015 reduction was Aratana Therapeutics, Inc., cutting an estimated $4.48M.
- Sio Capital Management fully exited GSK in Q3 2015, selling an estimated $10.6M.
- Sio Capital Management's ten largest holdings make up 57% of its $146M portfolio in Q3 2015.
- Sio Capital Management opened 10 new positions and closed 15 in Q3 2015.
- Sio Capital Management's portfolio value fell 28% quarter-over-quarter to $146M.
Based on Sio Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.